Synapse - Works

Results (2639)

A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant (ASCT)

Meeting Abstract

Foley, N.; Russler-Germain, D.; Watkins, M.; Jacobsen, E.; Moskowitz, A.; Cashen, A.; Fehniger, T.; Kahl, B.; Bartlett, N.; Ghobadi, A.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Pirtobrutinib in covalent BTK inhibitor pre-treated mantle cell lymphoma: Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment

Meeting Abstract

Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study

Meeting Abstract

Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Lisocabtagene maraleucel (liso-cel) in R/R MCL: Primary analysis results from the mcl cohort of the single-arm, multicenter, phase I seamless design TRANSCEND NHL 001 study

Meeting Abstract

Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

TRANSCEND FL: Phase II study results of lisocabtagene maraleucel (liso-cel) in patients with R/R follicular lymphoma (FL)

Meeting Abstract

Nastoupil, L. J.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Ortega, J. L. R.; Kuruvilla, J.; Jager, U.; Cartron, G.; Izutsu, K. I.; Dreyling, M.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory Waldenstrom macroglobulinemia

Meeting Abstract

Lewis, D. J.; Palomba, M. L.; Patel, M. R.; Eyre, T. A.; Jurczak, W.; Gastinne, T.; Ma, S.; Cohen, J. B.; Patel, K.; Brown, J. R.; more...
British Journal of Haematology (2023)

Fulltext@MSK | Save

Improved overall survival in stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1

Meeting Abstract

Collins, G. P.; Ansell, S. M.; Straus, D. J.; Connors, J. M.; Dlugosz-Danecka, M.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R.; more...
British Journal of Haematology (2023)

Fulltext@MSK | Save

Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: Extended follow-up from BRUIN

Meeting Abstract

Lewis, D. J.; Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutzu, K.; more...
British Journal of Haematology (2023)

Fulltext@MSK | Save

The efficacy of tixagevimab–cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: Insights from the Leukemia and Lymphoma Society Registry

Research Letter

Luttwak, E.; Noy, A.; Seshan, V.; Saltzman, L. A.; Greenberger, L. M.
Leukemia and Lymphoma (2023)

Fulltext@MSK | Save

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: A 3-year follow-up

Journal Article

Zinzani, P. L.; Santoro, A.; Gritti, G.; Brice, P.; Barr, P. M.; Kuruvilla, J.; Cunningham, D.; Kline, J.; Johnson, N. A.; Mehta-Shah, N.; more...
Blood Advances (2023)

Fulltext@MSK | Save